Abstract
Although transcatheter arterial chemoembolization (TACE) has been widely used as a palliative treatment for unresectable hepatocellular carcinoma (HCC), its actual efficacy and prognostic usefulness have not been clarified in past studies. The aim of the study is to investigate the efficacy, complications, and prognostic factors of the TACE in unresectable HCC patients. Thirty-two patients with unresectable HCC were treated with TACE. The procedure was performed with a combination of Lipiodol, doxorubicin, and cytomycin followed by gelatin-sponge particles embolization. CT-scan imaging and liver function tests (AST, ALT, ALP, BIL, and PT) were performed before and after the TACE. All patients were followed-up for 6-months. Of all patients, 1 and 11 patients respectively, exhibited a complete response (CR) and a partial response (PR) (response rate, CR+PR, 44%). Data have shown that tumor size, number of lesions and number of involved segments are significantly reduced after the TACE performance (P < 0.05). No significant clinical adverse effect was observed in patients after the intervention. Also, liver function tests including AST, ALT, ALP, BIL, and PT did not significantly differ before and after the intervention (P > 0.05)...Continue Reading
References
Jan 1, 1992·Cancer Chemotherapy and Pharmacology·S KawaiC Kuroda
Aug 15, 1985·Cancer·K OkudaK Ohnishi
May 1, 1994·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·L MondazziG Idèo
May 11, 1995·The New England Journal of Medicine·UNKNOWN Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire
Nov 1, 1995·World Journal of Surgery·R YamadaM Kimura
Jul 1, 1996·Annals of Surgery·T Lehnert, C Herfarth
May 1, 1996·Journal of Vascular and Interventional Radiology : JVIR·H NganW K Tso
Nov 1, 1996·Cardiovascular and Interventional Radiology·H J JaegerK D Mathias
May 15, 1997·Cancer·E AndoK Tanikawa
Mar 11, 1999·The New England Journal of Medicine·H B El-Serag, A C Mason
Jul 7, 1999·Journal of Vascular and Interventional Radiology : JVIR·B SolomonC Cope
Jan 5, 2000·Cancer·L LladóE Jaurrieta
Mar 29, 2002·Cancer·Annie O ChanChing-Lung Lai
Jun 7, 2002·Lancet·Josep M LlovetUNKNOWN Barcelona Liver Cancer Group
Dec 25, 2002·Japanese Journal of Clinical Oncology·Masafumi IkedaRyoko Iwata
Jan 24, 2003·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Josep M Llovet, Jordi Bruix
Feb 21, 2003·The British Journal of Surgery·C B O'SuilleabhainS T Fan
May 29, 2004·Anti-cancer Drugs·Diane L Reidy, Jonathan D Schwartz
Oct 28, 2004·Gastroenterology·Jordi BruixJosep M Llovet
Mar 12, 2005·CA: a Cancer Journal for Clinicians·D Max ParkinPaola Pisani
Dec 24, 2005·Journal of Vascular and Interventional Radiology : JVIR·Christos S GeorgiadesJean-Francois H Geschwind
Nov 15, 2006·Cardiovascular and Interventional Radiology·Laura MarelliAndrew K Burroughs
Oct 7, 2008·European Journal of Radiology·Thomas J VoglAhmed Abdelkader
Jun 24, 2009·Digestive Diseases·Geert MaleuxChris Verslype
Apr 21, 2010·Annals of Surgical Oncology·Eleni Liapi, Jean-Francois H Geschwind
Nov 12, 2010·Critical Reviews in Oncology/hematology·C Damiano Gadaleta, Girolamo Ranieri
Feb 15, 2013·Iranian Journal of Radiology : a Quarterly Journal Published by the Iranian Radiological Society·Hossein GhanaatiMadjid Shakiba
Feb 15, 2013·Iranian Journal of Radiology : a Quarterly Journal Published by the Iranian Radiological Society·Benan CaglayanGulsen Sarac
Sep 21, 2013·Iranian Journal of Radiology : a Quarterly Journal Published by the Iranian Radiological Society·Raman RajeshAzad Jaisiram
Dec 19, 2013·Iranian Journal of Radiology : a Quarterly Journal Published by the Iranian Radiological Society·Emin CakmakciZeki Karpat
Apr 3, 2014·Iranian Red Crescent Medical Journal·Hossein GhanaatiMadjid Shakiba